Legal & General Group Plc Lowers Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Legal & General Group Plc cut its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 1.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 391,388 shares of the biopharmaceutical company's stock after selling 7,065 shares during the period. Legal & General Group Plc owned about 0.25% of TG Therapeutics worth $11,781,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Invesco Ltd. boosted its stake in shares of TG Therapeutics by 1.2% in the 4th quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company's stock valued at $27,985,000 after buying an additional 10,989 shares during the period. Bank of Montreal Can lifted its stake in TG Therapeutics by 7.3% in the fourth quarter. Bank of Montreal Can now owns 20,016 shares of the biopharmaceutical company's stock worth $602,000 after acquiring an additional 1,357 shares during the last quarter. Shakespeare Wealth Management LLC acquired a new position in TG Therapeutics during the 4th quarter worth approximately $223,000. Federated Hermes Inc. lifted its position in shares of TG Therapeutics by 25.9% during the 4th quarter. Federated Hermes Inc. now owns 130,688 shares of the biopharmaceutical company's stock worth $3,934,000 after purchasing an additional 26,887 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its stake in shares of TG Therapeutics by 137.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after purchasing an additional 975 shares in the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have weighed in on the company. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX traded up $0.90 on Tuesday, reaching $37.87. The company's stock had a trading volume of 245,410 shares, compared to its average volume of 3,094,340. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32. The stock's 50-day moving average is $36.46 and its two-hundred day moving average is $32.09. The stock has a market capitalization of $5.95 billion, a P/E ratio of -378.73 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. The firm had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, sell-side analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.